Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Chinese males (age: 18\~45 yrs) with contraception during and 3 months post-dose. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse, ECG, and laboratory testing.~2. BMI between 19.0 and 28.0 kg/m² and body weight between 55 kg and 80 kg.~Exclusion Criteria:~1. suffering from active or latent tuberculosis or history of tuberculosis;~2. have heart disease or a history of heart disease;~3. suffer from mental illness or psychiatric history;~4. suffering from malignant tumors and their history;~5. suffering from herpes zoster and its history;~6. suffering from epilepsy and history of epilepsy;~7. be allergic to the drugs or its components with high sensitivity or allergic reaction, detection of ADA (+);~8. patients who lost blood or donated more than 200 mL within the first 2 months before the screening;~9. major surgery performed within 30 days prior to signing ICF;~10. live vaccine inoculation or vaccination within 12 weeks of screening, or possible administration of vaccine during screening and study visits;~11. previous application of adalimumab or its biosimilars, or anti-TNF alpha drugs;~12. participating in other clinical trials within the first 3 months of the trial;~13. abnormal immune function within 4 weeks before screening;~14. the presence of invasive systemic fungal infection or other opportunistic infections within 2 months prior to screening;~15. systemic or local infection, such as the risk of sepsis and / or known active inflammation within 2 months before screening;~16. 2 months before the screening, there were severe infections in the hospital and / or the need for intravenous antibiotics;~17. 4 or more upper respiratory tract infections occurred within 6 months prior to randomization;~18. hepatitis B surface antigen (HBsAg) positive; if hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, peripheral blood hepatitis B virus deoxyribonucleic acid (DNA) test \>0 IU/ml also ruled out;~19. hepatitis C virus (HCV) antibody positive;~20. human immunodeficiency virus (HIV) antibody positive;~21. Treponema pallidum (Treponema pallidum, TP) antibody positive;~22. anti nuclear antibody titer was 1:100 examination;~23. drug abusers, alcohol addicts;~24. , the researchers discretion of failure to follow the requirements of the program, instructions and research limitations, such as uncooperative attitude, unable to return to the Research Center for follow-up visits, or unable to complete the entire clinical study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HLX03 (Type: EXPERIMENTAL): There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
- Humira (Type: ACTIVE_COMPARATOR): There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).